Search results for "plate"

showing 10 items of 1689 documents

Evaluation of the concept of heterology in a monoclonal antibody-based ELISA utilizing direct hapten linkage to polystyrene microtiter plates.

2005

A series of new heterologous haptens has been synthesized and used as coating haptens in an antigen-immobilized immunoassay with a monoclonal antibody against atrazine. Coating was achieved by covalently linking the different haptens to a glutaraldehyde network directly bound to the polystyrene surface of a standard 96-well microtiter plate. With the assay designed in the antigen-immobilized format with direct chemical linkage of the hapten to the solid polystyrene surface well-defined hapten densities were achieved in all experiments. The results of different experiments with different coating haptens were comparable. Using different heterologous haptens it appears that the concept of hete…

medicine.drug_classImmunologyHeterologouschemical and pharmacologic phenomenaEnzyme-Linked Immunosorbent Assayengineering.materialMonoclonal antibodySensitivity and SpecificityMicrotiter platechemistry.chemical_compoundCoatingmedicineImmunology and AllergyChromatographyintegumentary systemmedicine.diagnostic_testChemistryAntibodies MonoclonalKineticsImmunoassayengineeringPolystyrenesAtrazineGlutaraldehydePolystyreneBinding Sites AntibodyHaptenHaptensJournal of immunological methods
researchProduct

INTEGRATED EFFICACY RESULTS FROM THE PHASE 2 AND PHASE 3 STUDIES WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA

2021

Objective: An integrated analysis based on the Phase 2 TITAN (NCT01151423) and Phase 3 HERCULES (NCT02553317) studies with caplacizumab (CPLZ) in acquired thrombotic thrombocytopenic purpura (aTTP) was performed to assess treatment differences on efficacy and safety outcomes that may have been undetected in the individual trials. Methodology: In both trials, patients with an acute episode of aTTP were randomized to receive CPLZ or placebo (PBO) in addition to therapeutic plasma exchange (TPE) and immunosuppression. All randomized patients from both studies were included in the integrated efficacy analyses (CPLZ: n=108; PBO: n=112), and those who received at least 1 dose of the study drug we…

medicine.medical_specialtyAcquired Thrombotic Thrombocytopenic PurpuraExacerbationbusiness.industrymedicine.medical_treatmentHazard ratioImmunosuppressionHematologyPlaceboGastroenterologyRefractoryInternal medicinemedicineImmunology and AllergyDiseases of the blood and blood-forming organsPlateletRC633-647.5CaplacizumabbusinessHematology, Transfusion and Cell Therapy
researchProduct

Update on Ischemic Heart Disease and Critical Care Cardiology

2014

This article summarizes the main developments reported in 2013 on ischemic heart disease, together with the most important innovations in the management of acute cardiac patients. 3.792 JCR (2014) Q2, 34/123 Cardiac & cardiovascular systems UEM

medicine.medical_specialtyAcute coronary syndromeCritical Caremedicine.medical_treatmentEnfermedad cardiovascularMyocardial InfarctionMyocardial IschemiaDiseaseCardiologíaTratamiento médicoPercutaneous Coronary InterventionSex FactorsSex factorsInternal medicinemedicineHumansMyocardial infarctionAcute Coronary SyndromeIntensive care medicinePatofisiologíaSistema cardiovascularbusiness.industryAge FactorsPercutaneous coronary interventionGeneral Medicinemedicine.diseasePrognosisPrimary PreventionConventional PCICardiologycardiovascular systemPlatelet aggregation inhibitorInfarto de miocardiobusinessIschemic heartPlatelet Aggregation InhibitorsRevista Española de Cardiología (English Edition)
researchProduct

Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.

2021

Abstract Aims Peripheral artery disease (PAD) patients suffer a high risk of major cardiovascular (CV) events, with athero-thrombo-embolism as the underlying pathophysiologic mechanism. Recently, two large randomized clinical trials evaluated the efficacy and safety of low-dose rivaroxaban twice daily plus aspirin in stable PAD outpatients and those immediately after peripheral revascularization. We sought to determine if the effects of low-dose rivaroxaban and aspirin compared to aspirin alone are consistent across this broad spectrum of PAD patients. Methods and results We conducted a random-effects meta-analysis of the COMPASS and VOYAGER randomized trials among 11 560 PAD patients (4996…

medicine.medical_specialtyAcute limb ischaemiaEpidemiologymedicine.medical_treatmentHemorrhageRevascularizationlaw.inventionBrain IschemiaPeripheral Arterial DiseaseRandomized controlled trialFibrinolytic AgentsRivaroxabanlawIschemiaInternal medicineMedicineHumansMyocardial infarctionAspirinRivaroxabanAspirinbusiness.industryHazard ratiomedicine.diseaseStrokeAmputationCardiologyDrug Therapy CombinationCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugFactor Xa InhibitorsEuropean journal of preventive cardiology
researchProduct

Does aspirin save lives in patients with COVID-19?

2021

‘An aspirin a day keeps the heart attack away’, is this also true in the prevention of thrombotic events associated with COVID-19? The rising COVID-19 pandemic has led to much work in the understanding of the pathophysiology of the disease. COVID-19 infection is thought to be an endothelial disease. Supporting this concept, it has been suggested that infection with SARS-CoV-2, the aetiological agent for COVID-19 infection, leads to a state mimicking Virchow’s triad, that is, vascular endothelial injury, blood stasis and clotting in concert with systemic inflammation resulting in systemic thrombosis. In keeping with this concept, moderately and critically ill patients with COVID-19 have been…

medicine.medical_specialtyAspirin2474business.industryCOVID-19healthcareInflammationDiseaseBlood stasisSystemic inflammationmedicine.diseaseThrombosisEditorialmedicineEtiologyPlatelet activationmedicine.symptomCardiology and Cardiovascular MedicineIntensive care medicinebusinessoutcome assessmentmedicine.drugHeart
researchProduct

Association between neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and C-reactive protein levels and metabolic status in patients with a bip…

2022

OBJECTIVES Neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and C-Reactive Protein (CRP) are markers of inflammation that are elevated in bipolar disorder (BD) and are also related to a higher risk of metabolic syndrome (MetS). This study aimed at investigating for the first time the association between NLR, PLR, and CRP and the metabolic status in BD. METHODS We assessed the association between biomarkers and the metabolic status: number of metabolic risk factors, presence of MetS, insulin sensitivity (Quantitative Insulin Sensitivity Check Index, QUICKI) and insulin resistance (Homeostatic Model Assessment for Insulin Resistance, HOMA-IR index), in a sample of 219 outpa…

medicine.medical_specialtyBipolar DisorderNeutrophilsLymphocyteInflammationGastroenterologyInsulin resistanceInternal medicinemedicineHumansLymphocytesBipolar disorderBiological PsychiatryRetrospective StudiesMetabolic SyndromebiologyPlatelet Countbusiness.industryC-reactive proteinQuantitative insulin sensitivity check indexmedicine.diseasePsychiatry and Mental healthC-Reactive Proteinmedicine.anatomical_structurebiology.proteinHomeostatic model assessmentInsulin ResistanceMetabolic syndromemedicine.symptombusinessBiomarkersThe World Journal of Biological Psychiatry
researchProduct


 Interventions to Reduce Platelet Prophylactic Transfusions in Patients with Hypoproliferative Thrombocytopenia: Providing Patients with the Fu…

2013

SUMMARY To reduce the infectious and immunologic complications of platelet transfusions in patients with hypoproliferative thrombocytopenia, three interventions have aimed to decrease the number of prophylactic platelet transfusions received by such patients for the prevention of bleeding. These are the reduction of the platelet count threshold triggering prophylactic transfusion, the administration of low-dose (as opposed to standard-dose) platelet transfusions, and the administration of therapeutic (as opposed to prophylactic) platelet transfusions. We demonstrate that—in terms of absolute risk reduction in all infectious and some immunologic complications of transfusion— patients can ben…

medicine.medical_specialtyBlood managementStandard of carebusiness.industryInternal medicineAbsolute risk reductionPsychological interventionMedicineIn patientPlateletbusinessGeneral Biochemistry Genetics and Molecular BiologySurgeryClinical Laboratory
researchProduct

Epidemiología de la transfusión sanguínea en los Servicios de Medicina Intensiva en España: «Transfusion Day»

2022

Objective To describe the transfusion practice in the ICUs in Spain, according to national and international recommendations (guidelines).DesignProspective, cross-sectional, multi-centre study.ScopeData collection was carried out by means of a questionnaire sent electronically to the Heads of Service of 111 ICUs in Spain.Participants1,448 patients were included, aged 61.8 (SD 15.7) years, 66.2% male, with an SOFA of 4.7 ± 3.8 and average stay of 10.62 ± 17.49 days.VariablesDemographic and clinical variables of the patients were collected, as well as variables related to the transfusion act.ResultsOf the 1,448 patients, 9.9% received al least one transfusion of any blood product, 3.7% fresh …

medicine.medical_specialtyBlood transfusionbusiness.industryAnemiamedicine.medical_treatmentHemodynamics030208 emergency & critical care medicineCritical Care and Intensive Care Medicinemedicine.disease03 medical and health sciencesRed blood cell0302 clinical medicinemedicine.anatomical_structure030228 respiratory systemBlood productInternal medicineEpidemiologyMedicinePlateletHemoglobinbusinessMedicina Intensiva
researchProduct

Minimally invasive plate fixation in femoral shaft fractures

1997

Bridge-plating with its advantages in terms of vascularity and bone healing is a well established procedure today in the treatment of comminuted femoral fractures. Bridge-plating means that the fracture site is not interfered with during the operative procedure. This paper introduces a surgical technique in which the plate is inserted through isolated proximal and distal incisions only, behind the vastus lateralis. Alignment is secured by the plates, the fracture site remains untouched, fixation and screw insertion is restricted to the proximal and distal main fragments. Longitudinal femoral fractures extending right into the trochanteric and or condylar areas are the main indication for mi…

medicine.medical_specialtyBone healingCondyleFracture Fixation InternalVascularitymedicineHumansMinimally Invasive Surgical ProceduresFemurFractures ComminutedGeneral Environmental ScienceFracture HealingOsteosynthesisbusiness.industrySoft tissuemusculoskeletal systemSurgeryRadiographyDiaphysismedicine.anatomical_structureOrthopedic surgeryGeneral Earth and Planetary SciencesFemalemedicine.symptombusinessBone PlatesFemoral FracturesFollow-Up StudiesInjury
researchProduct

Diminished Inhibition of Adhesion Molecule Expression in Prostacyclin Receptor Desensitized Human Platelets

1995

Long-term exposure of platelets to prostacyclin or iloprost (100nM, 3hr) results in receptor desensitization measured as decrease in 3H-iloprost binding sites by 47 +/- 14%. Desensitized platelets respond with an increased adhesion to endothelial cells. The mechanism of increased adhesiveness was studied by measuring the expression of the adhesion molecule CD62p (p-selectin; GMP140) on washed human platelets by flowcytometry. In thrombin stimulated platelets CD62p expression was dose-dependently reduced by iloprost. In receptor desensitized platelets IC50 for iloprost inhibition of thrombin-induced CD62p expression increased from 0.48 +/- 0.10 to 2.4 +/- 0.7 nM.

medicine.medical_specialtyChemistryProstacyclinAdhesionThrombinEndocrinologyInternal medicinecardiovascular systemmedicinelipids (amino acids peptides and proteins)PlateletReceptorProstacyclin receptorIC50circulatory and respiratory physiologyIloprostmedicine.drug
researchProduct